Rationale and Design of Randomized Clinical Trial for the Assessment of Macitentan Efficiency as Coadjuvant Treatment to Open and Endovascular Revascularization in Critical Limb Ischemia | Zendy

Ignacio Michel | Zendy; Joaquín De Haro | Zendy; Silvia Bleda | Zendy; Ilsem V. Laime | Zendy; Jhenifer Uyaguari | Zendy; Francisco Acín | Zendy

Open Access

Rationale and Design of Randomized Clinical Trial for the Assessment of Macitentan Efficiency as Coadjuvant Treatment to Open and Endovascular Revascularization in Critical Limb Ischemia

Author(s) -

Ignacio Michel,

Joaquín De Haro,

Silvia Bleda,

Ilsem V. Laime,

Jhenifer Uyaguari,

Francisco Acín

Publication year - 2016

Publication title -

clinical medicine insights cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 21

ISSN - 1179-5468

DOI - 10.4137/cmc.s38448

Subject(s) - medicine , critical limb ischemia , revascularization , amputation , randomized controlled trial , clinical endpoint , placebo , population , clinical trial , surgery , myocardial infarction , alternative medicine , environmental health , pathology

Critical limb ischemia (CLI) is defined by ischemic rest pain, tissue loss, or both, secondary to arterial insufficiency, and its prevalence is increasing mainly as a result of the worldwide high prevalence of diabetes. Currently, there are no available conclusive data on the efficacy of any coadjuvant therapy after revascularization procedure benefiting amputation and patency rates. Macitentan is an orally active dual endothelin (ET) receptor antagonist that may contribute to reduce the amputation rate and improve revascularization patency in CLI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research